Five-year real-world outcomes of short-course leukocyte-poor PRP versus standard conservative therapy in early-stage knee osteoarthritis
PLOS One · 02.04.2026 · 21 (4) · e0344749
DOI: 10.1371/journal.pone.0344749 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, online erschienen am 02.04.2026. Verfasst von Qiuping Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Platelet-Rich Plasma, Conservative Treatment, Leukocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Background
Platelet-rich plasma (PRP) is increasingly applied in knee osteoarthritis (KOA), but its long-term efficacy remains uncertain. This study assessed 5-year outcomes of intra-articular PRP compared with conventional therapy in early-stage KOA.
Methods
A retrospective cohort of 116 patients with bilateral KOA (Kellgren–Lawrence I–II) treated in 2019 was analyzed. Group A (n = 58) received standardized management plus three PRP injections, while Group B (n = 58) received standardized conservative management alone (NSAIDs and/or intra-articular hyaluronic acid), combined with education, exercise therapy, and weight management. Pain, function, and quality of life were evaluated by VAS, WOMAC, and SF-36 at baseline and 5 years.
Results
Both groups showed deterioration over 5 years. VAS increased from 4.64 ± 0.52 to 5.41 ± 1.17 in Group A and from 4.80 ± 0.59 to 5.44 ± 1.16 in Group B, without significant between-group difference ( P = 0.849). WOMAC and SF-36 scores also worsened similarly, with no intergroup significance ( P > 0.05). Intra-group analyses confirmed significant declines from baseline ( P < 0.001).
Conclusions
Although a short, single course of leukocyte-poor PRP did not yield sustained superiority over standardized conservative management at 5 years, this real-world study provides rare long-term comparative evidence that defines the temporal boundaries of PRP efficacy and underscores the need for maintenance or optimized dosing protocols in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Management Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, Sichuan, People's Republic of China.
- Affiliated Sport Hospital of Chengdu Sport University, Chengdu, Sichuan, People's Republic of China.
- Department of Orthopedics, Chongqing General Hospital, Chongqing University, Chongqing, People's Republic of China.
ORCID-Profile: Qiuping Yu, Junli Liu
Förderung
- Natural Science Foundation of Chongqing
Zitieren
APA
Yu, Q., Wen, C., & Liu, J. (2026). Five-year real-world outcomes of short-course leukocyte-poor PRP versus standard conservative therapy in early-stage knee osteoarthritis. PLOS One, 21(4), e0344749. https://doi.org/10.1371/journal.pone.0344749
Vancouver
Yu Q, Wen C, Liu J. Five-year real-world outcomes of short-course leukocyte-poor PRP versus standard conservative therapy in early-stage knee osteoarthritis. PLOS One. 2026;21(4):e0344749. doi:10.1371/journal.pone.0344749
BibTeX
@article{Yu2026,
author = {Yu, Qiuping and Wen, Chenghong and Liu, Junli},
title = {Five-year real-world outcomes of short-course leukocyte-poor PRP versus standard conservative therapy in early-stage knee osteoarthritis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0344749},
doi = {10.1371/journal.pone.0344749}
}
EUVIMED